Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Expression of OV-6 in primary colorectal cancer and rectal cancer with preoperative chemoradiotherapy: a clinicopathological study.

Lin CH, Liu CH, Tsai HL, Wang JY, Tsai HP, Chai CY.

Histopathology. 2013 Apr;62(5):742-51. doi: 10.1111/his.12075. Epub 2013 Feb 28.

PMID:
23445514
2.

Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision.

Lee JH, Jang HS, Kim JG, Cho HM, Shim BY, Oh ST, Yoon SC, Kim YS, Choi BO, Kim SH.

Ann Surg Oncol. 2012 Apr;19(4):1213-21. doi: 10.1245/s10434-011-2062-z. Epub 2011 Sep 21.

PMID:
21935746
3.

Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.

Lin CY, Tian YF, Wu LC, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH.

J Clin Pathol. 2012 Aug;65(8):687-92. doi: 10.1136/jclinpath-2012-200786. Epub 2012 May 8.

PMID:
22569540
4.

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.

Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ.

Dis Colon Rectum. 2003 Feb;46(2):192-202.

PMID:
12576893
5.

Is the N1c category of the new American Joint Committee on cancer staging system applicable to patients with rectal cancer who receive preoperative chemoradiotherapy?

Song JS, Chang HJ, Kim DY, Kim SY, Baek JY, Park JW, Park SC, Choi HS, Oh JH.

Cancer. 2011 Sep 1;117(17):3917-24. doi: 10.1002/cncr.25968. Epub 2011 Feb 24.

6.

Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.

Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY.

Ann Surg. 2007 Dec;246(6):1040-6.

PMID:
18043108
7.

Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection.

Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, Chen CW, Wang JY.

J Surg Oncol. 2009 Dec 15;100(8):736-43. doi: 10.1002/jso.21404.

PMID:
19757443
8.

Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.

Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77.

PMID:
15708244
9.

Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61. Epub 2007 Apr 18.

PMID:
17445998
10.

Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer.

Zhou YJ, Xie YT, Gu J, Yan L, Guan GX, Liu X.

Eur J Surg Oncol. 2011 Dec;37(12):1078-84. doi: 10.1016/j.ejso.2011.08.139. Epub 2011 Sep 22.

PMID:
21944050
11.

A novel data-driven prognostic model for staging of colorectal cancer.

Manilich EA, Kiran RP, Radivoyevitch T, Lavery I, Fazio VW, Remzi FH.

J Am Coll Surg. 2011 Nov;213(5):579-588, 588.e1-2. doi: 10.1016/j.jamcollsurg.2011.08.006. Epub 2011 Sep 16.

PMID:
21925905
12.

ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer.

Avoranta ST, Korkeila EA, Ristamäki RH, Syrjänen KJ, Carpén OM, Pyrhönen SO, Sundström JT.

Hum Pathol. 2013 Jun;44(6):966-74. doi: 10.1016/j.humpath.2012.10.003. Epub 2013 Jan 17.

PMID:
23332924
13.

Apoptotic proteins as prognostic markers and indicators of radiochemosensitivity in stage II/III rectal cancers.

Fucini C, Messerini L, Saieva C, Orzalesi L, Carroni V, Bartolini N.

Colorectal Dis. 2012 Feb;14(2):e64-71. doi: 10.1111/j.1463-1318.2011.02763.x.

PMID:
21848899
14.

Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer.

Shioya M, Takahashi T, Ishikawa H, Sakurai H, Ebara T, Suzuki Y, Saitoh J, Ohno T, Asao T, Kuwano H, Nakano T.

J Radiat Res. 2011;52(6):821-7.

15.

Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.

Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ.

Ann Surg Oncol. 2009 Feb;16(2):297-303. doi: 10.1245/s10434-008-0221-7. Epub 2008 Dec 3.

PMID:
19050975
16.

The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer.

Perez RO, São Julião GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, Gama-Rodrigues JJ, Cecconello I.

Dis Colon Rectum. 2009 Jun;52(6):1137-43. doi: 10.1007/DCR.0b013e31819ef76b.

PMID:
19581858
17.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
18.

Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy.

Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, Okugawa Y, Hiro J, Uchida K, Mohri Y, Kusunoki M.

Int J Oncol. 2012 Nov;41(5):1643-52. doi: 10.3892/ijo.2012.1598. Epub 2012 Aug 22.

PMID:
22923071
19.

Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.

Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH, Choi D, Jang SJ.

Ann Surg Oncol. 2007 Dec;14(12):3453-9. Epub 2007 Sep 20.

PMID:
17882496
20.

P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.

Theodoropoulos GE, Karafoka E, Papailiou JG, Stamopoulos P, Zambirinis CP, Bramis K, Panoussopoulos SG, Leandros E, Bramis J.

Anticancer Res. 2009 Feb;29(2):785-91.

Supplemental Content

Support Center